Menu
  • Join
  • Login
  • Contact
 

Search abstracts


CYP2C19 GENOTYPES AND THERAPEUTIC DRUG MONITORING OF VORICONAZOLE IN PATIENTS WITH MULTIPLE MYELOMA

  • At: 2019 FIP Congress in AbuDhabi (United Arab Emirates)
  • Type: Poster
  • By: TAN, Zhiyuan (Peking University Third Hospital, Pharmacy, China)
  • Co-author(s): Zhiyuan Tan: Pharmacy, Peking University Third Hospital, BEIJING, China;Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, BEIJING, China
    Wei Liu: Pharmacy, Peking University Third Hospital, BEIJING, China;Therapeutic Drug Monitoring and Clinical Toxicology Center, Peking University, BEIJING, China
    Weilong Shi: Pharmacy , Peking University Third Hospital , BEIJING, China
    Kai Hu: Hematology, Peking University Third Hospital , BEIJING, China
    Rongsheng Zhao: Pharmacy, Peking University Third Hospital, BEIJING, China;Therapeutic Drug Monitoring and Clinical Toxicology Center, Peking University , BEIJING, China
  • Abstract:

    Background

    New agents based intensive chemotherapy has improved the survival of multiple myeloma (MM), while invasive fungal diseases (IFD) are important causes of morbidity and mortality due to MM-related or treatment-related immunodeficiency. Voriconazole (VRZ) is a broad-spectrum first-line agent for IFD with favorable efficacy, but its..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses